首页> 美国卫生研究院文献>Proceedings of the National Academy of Sciences of the United States of America >The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor.
【2h】

The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor.

机译:低密度脂蛋白受体相关蛋白介导组织因子途径抑制剂的细胞降解。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor (LRP) is a cell-surface glycoprotein of 4525 amino acids that functions as a hepatic endocytosis receptor for several plasma proteins. These include alpha 2-macroglobulin-protease complexes, free plasminogen activators as well as plasminogen activators complexed with their inhibitors, and beta-migrating very low density lipoproteins complexed with either apolipoprotein E or lipoprotein lipase. In the current study we used human and rat hepatoma cell lines to demonstrate that LRP can mediate the degradation of tissue factor pathway inhibitor (TFPI), a Kunitz-type plasma serine protease inhibitor that regulates tissue factor-induced blood coagulation. The cellular degradation of 125I-labeled TFPI (125I-TFPI) was inhibited more than 80% both by antibodies directed against LRP and by the LRP-associated 39-kDa protein, a protein that inhibits the binding and/or cell-mediated degradation of all ligands by LRP. Using rat hepatoma cells, we report that at 4 degrees C, 125I-TFPI binds to approximately 2 x 10(6) sites per cell with an equilibrium dissociation constant of approximately 30 nM. 125I-TFPI binding to the cell surface is not inhibited by the 39-kDa protein. Taken together, our results suggest that TFPI binds to an as-yet-unidentified cell surface molecule. After binding, LRP mediates the cellular degradation of TFPI.
机译:低密度脂蛋白受体相关蛋白/α2-巨球蛋白受体(LRP)是一种具有4525个氨基酸的细胞表面糖蛋白,可作为多种血浆蛋白的肝内吞受体。这些包括α2-巨球蛋白-蛋白酶复合物,游离的纤溶酶原激活剂以及与它们的抑制剂复合的纤溶酶原激活剂,以及与载脂蛋白E或脂蛋白脂酶复合的β迁移极低密度脂蛋白。在当前的研究中,我们使用了人类和大鼠的肝癌细胞系来证明LRP可以介导组织因子途径抑制剂(TFPI)的降解,TFPI是一种Kunitz型血浆丝氨酸蛋白酶抑制剂,可调节组织因子诱导的血液凝固。 125I标记的TFPI(125I-TFPI)的细胞降解受到针对LRP的抗体和LRP相关的39 kDa蛋白(一种抑制LRP结合和/或细胞介导的降解的蛋白)的抑制超过80%。所有配体均由LRP合成。使用大鼠肝癌细胞,我们报告在4摄氏度,每个细胞125I-TFPI结合约2 x 10(6)个位点,平衡解离常数约为30 nM。 39 IkDa蛋白不会抑制125 I-TFPI与细胞表面的结合。两者合计,我们的结果表明TFPI结合到尚未确定的细胞表面分子。结合后,LRP介导TFPI的细胞降解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号